Vericel (VCEL) Revenue (2011 - 2026)
Vericel (VCEL) posted Revenue of $77.5 million for Q2 2026, up 13.2% sequentially from $68.4 million in Q1 2026, and up 22.48% YoY from $63.2 million in Q2 2025.
Vericel (VCEL) Revenue (2011 - 2026) Analysis & Trends
Vericel has reported Revenue for 16 years, with the latest figure at $77.5 million in Q2 2026.
- Quarterly Revenue rose 22.48% year-over-year to $77.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $306.3 million (up 22.95% YoY) and the FY2025 annual result came in at $276.3 million, up 16.45% from the prior year.
- Revenue rose to $77.5 million in Q2 2026 per VCEL's latest filing, from $68.4 million in the prior quarter.
- Over five years, Revenue peaked at $92.9 million in Q4 2025 and troughed at $36.1 million in Q1 2022.
- A 5-year average of $56.7 million and a median of $52.7 million in 2022 frame the typical range for Revenue.
- The sharpest annual moves came in 2022 and 2026: Revenue retreated 6.26% in 2022, then soared 30.09% in 2026.
- Over 5 years, Revenue stood at $52.7 million in 2022, then gained by 23.35% to $65.0 million in 2023, then grew by 15.97% to $75.4 million in 2024, then rose by 23.27% to $92.9 million in 2025, then fell by 16.64% to $77.5 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $77.5 million, $68.4 million, and $92.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 77.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77.46 Mn |
| Mar 31, 2026 | 68.43 Mn |
| Dec 31, 2025 | 92.92 Mn |
| Sep 30, 2025 | 67.50 Mn |
| Jun 30, 2025 | 63.24 Mn |
| Mar 31, 2025 | 52.60 Mn |
| Dec 31, 2024 | 75.38 Mn |
| Sep 30, 2024 | 57.91 Mn |
| Jun 30, 2024 | 52.66 Mn |
| Mar 31, 2024 | 51.28 Mn |
| Dec 31, 2023 | 65.00 Mn |
| Sep 30, 2023 | 45.58 Mn |
| Jun 30, 2023 | 45.92 Mn |
| Mar 31, 2023 | 41.02 Mn |
| Dec 31, 2022 | 52.69 Mn |
| Sep 30, 2022 | 38.33 Mn |
| Jun 30, 2022 | 36.83 Mn |
| Mar 31, 2022 | 35.85 Mn |
| Dec 31, 2021 | 47.59 Mn |
| Sep 30, 2021 | 33.72 Mn |